Raymond James initiated coverage of Revolution Medicines with an Outperform rating and $30 price target.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on RVMD:
- Revolution Medicines price target lowered to $28 from $32 at H.C. Wainwright
- Revolution Medicines announces Horning joined board of directors
- Revolution Medicines completes acquisition of EQRx
- Revolution Medicines Completes Acquisition of EQRx
- Revolution Medicines and EQRx Stockholders Approve EQRx Acquisition